CommentExtended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions
References (8)
- et al.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Lancet
(2017) - et al.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol
(2016) - et al.
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831
J Clin Oncol
(2014) - et al.
Adjuvant trastuzumab in HER2-positive breast cancer
N Engl J Med
(2011)
There are more references available in the full text version of this article.
Cited by (1)
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
2019, Clinical Drug Investigation
© 2017 Elsevier Ltd. All rights reserved.